Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P860004/S458

SynchroMed Infusion System, Ascenda Intrathecal Catheters

Medtronic, Inc. · Decision date Oct 27, 2026

FDA DECISIONP860004/S458

What did the FDA approve?

FDA records P860004/S458 as a supplement to PMA P860004, with the supplement type “Normal 180 Day Track”. The recorded decision is approval, dated Oct 27, 2026.

FDA approval order statement

software changes to address Z-1506-2025 in the Model A820 (Personal Therapy Manager) Application
Regulatory pathway
PMA supplement
Supplement type
Normal 180 Day Track
Clinical specialty
General Hospital
Decision date
Oct 27, 2026
FDA change category
Change Design/Components/Specifications/Material

FDA source record

Regulatory record facts

Identifier
P860004/S458
Regulatory pathway
PMA supplement
Product code
LKK
Decision code
APPR
Decision date
Oct 27, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Pump, infusion, implanted, programmable.

Product code
LKK
FDA device class
3

For the original device and its historical approval scope, see PMA P860004. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P860004 · Original PMA

    MEDTRONIC(R) SYNCHROMED(TM) PUMP & INFUSION SYSTEM

  2. P860004/S458 received

    Application receipt date recorded by FDA.

  3. P860004/S462 · Related supplement

    SynchroMed Infusion System, Ascenda Intrathecal Catheters

  4. P860004/S458 · FDA decision

    Normal 180 Day Track

  5. P860004/S464 · Related supplement

    SynchroMed Infusion System, Ascenda Intrathecal Catheters TDD (Drug Delivery Infusion Pump 8667), TDD (Drug Delivery I

  6. P860004/S465 · Related supplement

    SynchroMed Infusion System, Ascenda Intrathecal Catheters

Timeline entries are records held by MedtechLedger for P860004. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P860004

Explore the linked device profile

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Medtronic, Inc.

Headquarters
Not reported
Brand website
medtronic.com
FDA applicant address
7000 Central Ave., NE, Minneapolis, MN, 55432

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records